Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-517 (Cervarix) Safety and Immunogenicity in HPV-Positive Women
NCT00263744Phase 2Completed
- Sponsor
- MedImmune
- Start
- Nov 1999
- Primary completion
- Apr 2001
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, sponsored by MedImmune. Started Nov 1999; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00263744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263744.